Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus
This work aimed to provide recombinant Lactococcus lactis as a potential live vector for the manufacture of recombinant Brucella abortus (rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were e...
Gespeichert in:
| Veröffentlicht in: | Archives of microbiology 2023-04, Vol.205 (4), p.122 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 122 |
| container_title | Archives of microbiology |
| container_volume | 205 |
| creator | Fatehi, Zahra Doosti, Abbas Jami, Mohammad Saeid |
| description | This work aimed to provide recombinant
Lactococcus
lactis
as a potential live vector for the manufacture of recombinant
Brucella
abortus
(rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant
L.
lactis
. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the
L.
lactis
-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (
P
|
| doi_str_mv | 10.1007/s00203-023-03471-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_sprin</sourceid><recordid>TN_cdi_proquest_journals_2788566234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788566234</sourcerecordid><originalsourceid>FETCH-LOGICAL-p157t-d2af15d9a43a624bcdc41650ac57caaaa397ad7079dac14bb269e90e78fb02133</originalsourceid><addsrcrecordid>eNpFkc9q3DAQxkVoINukL9CToJf24GYk2ZZ9bEKTFhZySAK5mbGszSrI0lZ_NqSvlpeLdrc0AqEB_b5vhvkI-czgOwOQ5xGAg6iAlytqyar2iCxYLXgFkj98IAsQwKuuF-KEfIzxCYDxrusW5PUmoKVbVMo4TMY7-mzSmjq_1ZYuUSWvvFI52lKaSOesfCwCa7aabnX5DlXUKuhk3CO9CFlpa5HaPONf4zSNLy6tMWr69WJ5-41ugk_aOGrcVMhI13n2u_7oJrpTZouBmnnORbpn1X4kfETjYvrvj6MPKcczcrxCG_Wnf-8pub_6eXf5q1reXP--_LGsNqyRqZo4rlgz9VgLbHk9qknVrG0AVSMVliN6iZME2U-oWD2OvO11D1p2qxE4E-KUfDn4lpH-ZB3T8ORzcKXlwGXXNW3LRV0ocaDiJpRl6PBOMRh2KQ2HlIaS0rBPaWjFGzJyi7o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788566234</pqid></control><display><type>article</type><title>Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus</title><source>SpringerNature Complete Journals</source><creator>Fatehi, Zahra ; Doosti, Abbas ; Jami, Mohammad Saeid</creator><creatorcontrib>Fatehi, Zahra ; Doosti, Abbas ; Jami, Mohammad Saeid</creatorcontrib><description>This work aimed to provide recombinant
Lactococcus
lactis
as a potential live vector for the manufacture of recombinant
Brucella
abortus
(rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant
L.
lactis
. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the
L.
lactis
-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (
P
< 0.001) compared to the PBS control group. Vaccinated mice showed higher levels of IFN-γ, TNFα, IL-4, and IL-10 in samples obtained on days 14 and 28, after receiving the
L.
lactis
-pNZ8148-BLS-Usp45 and IRBA vaccines (
P
< 0.001). The inflammatory reaction caused less severe spleen injuries, alveolar edema, lymphocyte infiltration, and morphological damage in the target group's spleen sections. Based on our findings, an oral or subunit-based vaccine against brucellosis might be developed using
L.
lactis
-pNZ8148-BLS-Usp45 as a novel, promising, and safe alternative to the live attenuated vaccines now available.</description><identifier>ISSN: 0302-8933</identifier><identifier>EISSN: 1432-072X</identifier><identifier>DOI: 10.1007/s00203-023-03471-6</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Alveoli ; Antibodies ; Antigens ; Biochemistry ; Biomedical and Life Sciences ; Biotechnology ; Brucellosis ; Cell Biology ; Ecology ; Edema ; Enzyme-linked immunosorbent assay ; Immunization ; Immunogenicity ; Immunoglobulin G ; Inflammation ; Interleukin 10 ; Interleukin 4 ; Life Sciences ; Lumazine synthase ; Lymphocytes ; Microbial Ecology ; Microbiology ; Original Paper ; Priming ; Proteins ; Solubility ; Spleen ; Target groups ; Vaccines ; γ-Interferon</subject><ispartof>Archives of microbiology, 2023-04, Vol.205 (4), p.122</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p157t-d2af15d9a43a624bcdc41650ac57caaaa397ad7079dac14bb269e90e78fb02133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00203-023-03471-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00203-023-03471-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Fatehi, Zahra</creatorcontrib><creatorcontrib>Doosti, Abbas</creatorcontrib><creatorcontrib>Jami, Mohammad Saeid</creatorcontrib><title>Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus</title><title>Archives of microbiology</title><addtitle>Arch Microbiol</addtitle><description>This work aimed to provide recombinant
Lactococcus
lactis
as a potential live vector for the manufacture of recombinant
Brucella
abortus
(rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant
L.
lactis
. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the
L.
lactis
-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (
P
< 0.001) compared to the PBS control group. Vaccinated mice showed higher levels of IFN-γ, TNFα, IL-4, and IL-10 in samples obtained on days 14 and 28, after receiving the
L.
lactis
-pNZ8148-BLS-Usp45 and IRBA vaccines (
P
< 0.001). The inflammatory reaction caused less severe spleen injuries, alveolar edema, lymphocyte infiltration, and morphological damage in the target group's spleen sections. Based on our findings, an oral or subunit-based vaccine against brucellosis might be developed using
L.
lactis
-pNZ8148-BLS-Usp45 as a novel, promising, and safe alternative to the live attenuated vaccines now available.</description><subject>Alveoli</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biotechnology</subject><subject>Brucellosis</subject><subject>Cell Biology</subject><subject>Ecology</subject><subject>Edema</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Inflammation</subject><subject>Interleukin 10</subject><subject>Interleukin 4</subject><subject>Life Sciences</subject><subject>Lumazine synthase</subject><subject>Lymphocytes</subject><subject>Microbial Ecology</subject><subject>Microbiology</subject><subject>Original Paper</subject><subject>Priming</subject><subject>Proteins</subject><subject>Solubility</subject><subject>Spleen</subject><subject>Target groups</subject><subject>Vaccines</subject><subject>γ-Interferon</subject><issn>0302-8933</issn><issn>1432-072X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpFkc9q3DAQxkVoINukL9CToJf24GYk2ZZ9bEKTFhZySAK5mbGszSrI0lZ_NqSvlpeLdrc0AqEB_b5vhvkI-czgOwOQ5xGAg6iAlytqyar2iCxYLXgFkj98IAsQwKuuF-KEfIzxCYDxrusW5PUmoKVbVMo4TMY7-mzSmjq_1ZYuUSWvvFI52lKaSOesfCwCa7aabnX5DlXUKuhk3CO9CFlpa5HaPONf4zSNLy6tMWr69WJ5-41ugk_aOGrcVMhI13n2u_7oJrpTZouBmnnORbpn1X4kfETjYvrvj6MPKcczcrxCG_Wnf-8pub_6eXf5q1reXP--_LGsNqyRqZo4rlgz9VgLbHk9qknVrG0AVSMVliN6iZME2U-oWD2OvO11D1p2qxE4E-KUfDn4lpH-ZB3T8ORzcKXlwGXXNW3LRV0ocaDiJpRl6PBOMRh2KQ2HlIaS0rBPaWjFGzJyi7o</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Fatehi, Zahra</creator><creator>Doosti, Abbas</creator><creator>Jami, Mohammad Saeid</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope></search><sort><creationdate>20230401</creationdate><title>Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus</title><author>Fatehi, Zahra ; Doosti, Abbas ; Jami, Mohammad Saeid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p157t-d2af15d9a43a624bcdc41650ac57caaaa397ad7079dac14bb269e90e78fb02133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alveoli</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biotechnology</topic><topic>Brucellosis</topic><topic>Cell Biology</topic><topic>Ecology</topic><topic>Edema</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Inflammation</topic><topic>Interleukin 10</topic><topic>Interleukin 4</topic><topic>Life Sciences</topic><topic>Lumazine synthase</topic><topic>Lymphocytes</topic><topic>Microbial Ecology</topic><topic>Microbiology</topic><topic>Original Paper</topic><topic>Priming</topic><topic>Proteins</topic><topic>Solubility</topic><topic>Spleen</topic><topic>Target groups</topic><topic>Vaccines</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fatehi, Zahra</creatorcontrib><creatorcontrib>Doosti, Abbas</creatorcontrib><creatorcontrib>Jami, Mohammad Saeid</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><jtitle>Archives of microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fatehi, Zahra</au><au>Doosti, Abbas</au><au>Jami, Mohammad Saeid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus</atitle><jtitle>Archives of microbiology</jtitle><stitle>Arch Microbiol</stitle><date>2023-04-01</date><risdate>2023</risdate><volume>205</volume><issue>4</issue><spage>122</spage><pages>122-</pages><issn>0302-8933</issn><eissn>1432-072X</eissn><abstract>This work aimed to provide recombinant
Lactococcus
lactis
as a potential live vector for the manufacture of recombinant
Brucella
abortus
(rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant
L.
lactis
. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the
L.
lactis
-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (
P
< 0.001) compared to the PBS control group. Vaccinated mice showed higher levels of IFN-γ, TNFα, IL-4, and IL-10 in samples obtained on days 14 and 28, after receiving the
L.
lactis
-pNZ8148-BLS-Usp45 and IRBA vaccines (
P
< 0.001). The inflammatory reaction caused less severe spleen injuries, alveolar edema, lymphocyte infiltration, and morphological damage in the target group's spleen sections. Based on our findings, an oral or subunit-based vaccine against brucellosis might be developed using
L.
lactis
-pNZ8148-BLS-Usp45 as a novel, promising, and safe alternative to the live attenuated vaccines now available.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00203-023-03471-6</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-8933 |
| ispartof | Archives of microbiology, 2023-04, Vol.205 (4), p.122 |
| issn | 0302-8933 1432-072X |
| language | eng |
| recordid | cdi_proquest_journals_2788566234 |
| source | SpringerNature Complete Journals |
| subjects | Alveoli Antibodies Antigens Biochemistry Biomedical and Life Sciences Biotechnology Brucellosis Cell Biology Ecology Edema Enzyme-linked immunosorbent assay Immunization Immunogenicity Immunoglobulin G Inflammation Interleukin 10 Interleukin 4 Life Sciences Lumazine synthase Lymphocytes Microbial Ecology Microbiology Original Paper Priming Proteins Solubility Spleen Target groups Vaccines γ-Interferon |
| title | Oral vaccination with novel Lactococcuslactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucellaabortus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T08%3A07%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20vaccination%20with%20novel%20Lactococcuslactis%20mucosal%20live%20vector-secreting%20Brucella%20lumazine%20synthase%20(BLS)%20protein%20induces%20humoral%20and%20cellular%20immune%20protection%20against%20Brucellaabortus&rft.jtitle=Archives%20of%20microbiology&rft.au=Fatehi,%20Zahra&rft.date=2023-04-01&rft.volume=205&rft.issue=4&rft.spage=122&rft.pages=122-&rft.issn=0302-8933&rft.eissn=1432-072X&rft_id=info:doi/10.1007/s00203-023-03471-6&rft_dat=%3Cproquest_sprin%3E2788566234%3C/proquest_sprin%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2788566234&rft_id=info:pmid/&rfr_iscdi=true |